EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study

Adnan Khattak iD, Matteo S Carlino iD, Tarek Meniawy iD, George Ansstas iD, Matthew H Taylor iD, Kevin B Kim iD, Meredith McKean iD, Georgina V Long iD, Ryan J Sullivan iD, Mark Faries iD, Thuy T Tran iD, C Lance Cowey und 10 weitere

Journal of Clinical Oncology · 10.09.2026 · 44 (26) · 2482-2489

DOI: 10.1200/jco-26-00835 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2026. Verfasst von Adnan Khattak und 21 weiteren Autor:innen. Beteiligte Einrichtung: One Clinical Research, Hollywood Private Hospital and Edith Cowan University, Perth, WA, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Melanoma, Skin Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intismeran autogene (intismeran; formerly V940 or mRNA-4157) is an mRNA-based individualized neoantigen therapy. We report 5-year outcomes of intismeran plus pembrolizumab from the phase IIb KEYNOTE-942 study (ClinicalTrials.gov identifier: NCT03897881 ). Eligible patients with resected stage IIIB to IV cutaneous melanoma were randomly assigned 2:1 to receive nine doses of intramuscular intismeran 1 mg once every 3 weeks plus 18 doses of intravenous pembrolizumab 200 mg once every 3 weeks or 18 doses of intravenous pembrolizumab 200 mg once every 3 weeks. The primary end point was recurrence-free survival (RFS); secondary end points included distant metastasis-free survival (DMFS) and safety. Five-year analyses were descriptive. Among 157 randomly assigned patients (intismeran plus pembrolizumab, n = 107; pembrolizumab, n = 50), the median planned follow-up at data cutoff (December 15, 2025) was 60.3 (range, 50.5-76.4) months. Intismeran plus pembrolizumab continued to prolong RFS (hazard ratio [HR], 0.510 [95% CI, 0.294 to 0.887) and DMFS (HR, 0.411 [95% CI, 0.200 to 0.843]), with a favorable trend in overall survival (HR, 0.471 [95% CI, 0.165 to 1.345]) versus pembrolizumab. Safety profile continued to be manageable, with no new safety signals. Intismeran plus pembrolizumab was associated with increased T-cell receptor clonality and novel clonotypes versus pembrolizumab; greater novel clone expansion was observed in patients without versus with recurrence in the combination arm. After a 5-year follow-up, intismeran plus pembrolizumab demonstrated sustained, durable treatment benefits versus pembrolizumab alone in resected high-risk melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedMelanomaSkin NeoplasmsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and over

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • One Clinical Research, Hollywood Private Hospital and Edith Cowan University, Perth, WA, Australia.
  • Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia.
  • Saint John of God Subiaco Hospital, Subiaco, WA, Australia.
  • Washington University School of Medicine, St Louis, MO.
  • Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR.
  • California Pacific Medical Center Research Institute, San Francisco, CA.

ORCID-Profile: Adnan Khattak, Matteo S Carlino, Tarek Meniawy, George Ansstas, Matthew H Taylor, Kevin B Kim, Meredith McKean, Georgina V Long, Ryan J Sullivan, Mark Faries, Thuy T Tran, Theresa Medina, Thomas Jemielita, Jacky Chow, Laureen S Ojalvo, Janice M Mehnert

Zitieren

APA

Khattak, A., Carlino, M. S., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., Faries, M., Tran, T. T., Cowey, C. L., Pecora, A., Medina, T., Atkinson, V., Krepler, C., Jemielita, T., Mao, H., Chow, J., …, & KEYNOTE-942 Investigators (2026). Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study. Journal of Clinical Oncology, 44(26), 2482-2489. https://doi.org/10.1200/jco-26-00835

Vancouver

Khattak A, Carlino MS, Meniawy T, Ansstas G, Taylor MH, Kim KB, et al. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study. Journal of Clinical Oncology. 2026;44(26):2482-2489. doi:10.1200/jco-26-00835

BibTeX
@article{Khattak2026,
  author = {Khattak, Adnan and Carlino, Matteo S and Meniawy, Tarek and Ansstas, George and Taylor, Matthew H and Kim, Kevin B and McKean, Meredith and Long, Georgina V and Sullivan, Ryan J and Faries, Mark and Tran, Thuy T and Cowey, C Lance and Pecora, Andrew and Medina, Theresa and Atkinson, Victoria and Krepler, Clemens and Jemielita, Thomas and Mao, Huzhang and Chow, Jacky and Ojalvo, Laureen S and Mehnert, Janice M and KEYNOTE-942 Investigators, KEYNOTE-942 Investigators},
  title = {Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {26},
  pages = {2482--2489},
  doi = {10.1200/jco-26-00835}
}
Kostenlos starten →